MET inhibitor Compound 1
Modify Date: 2025-09-19 17:44:49
MET inhibitor Compound 1 structure
|
Common Name | MET inhibitor Compound 1 | ||
|---|---|---|---|---|
| CAS Number | 1208248-23-0 | Molecular Weight | 449.426 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H17F2N9O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MET inhibitor Compound 1A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively; demonstrates potent, broad spectrum activity against MET mutants (V1110I, H1112Y, L1195V, Y1235D, D1228H and M1250T) with IC50 of <1 nM-57 nM, and Y1230 mutants with moderate potency (IC50=25-280 nM); displays >50-fold selectivity in a panel of 130 kinases with exception of Fms and TrkA/B/C; inhibits MET-dependent tumor cell growth in vivo through decreasing phosphorylaed MET. |
| Name | MET inhibitor Compound 1 |
|---|
| Description | A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively; demonstrates potent, broad spectrum activity against MET mutants (V1110I, H1112Y, L1195V, Y1235D, D1228H and M1250T) with IC50 of <1 nM-57 nM, and Y1230 mutants with moderate potency (IC50=25-280 nM); displays >50-fold selectivity in a panel of 130 kinases with exception of Fms and TrkA/B/C; inhibits MET-dependent tumor cell growth in vivo through decreasing phosphorylaed MET. |
|---|---|
| References | References 1. Farrell PJ, et al. Mol Cancer Ther. 2017 Jul;16(7):1269-1278. View Related Products by Target c-Met (HGFR) |
| Molecular Formula | C21H17F2N9O |
|---|---|
| Molecular Weight | 449.426 |
| InChIKey | RLLSEIXUTRQGNA-UHFFFAOYSA-N |
| SMILES | Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5nc(NC(=O)C6CC6)cn5n4)n3c2)cn1 |